Anastasia Khvorova’s lab at U-Mass. Chan Medical School shows how quickly the administration is dismantling an 80-year partnership that made the U.S. a scientific superpower.

Three-quarters of US-based researchers and graduate students are considering working abroad, according to a recent study.

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise...

STAT reviewed dozens of studies, interviewed chronic disease experts, and landed on three focus areas for Robert F. Kennedy Jr. to boost health.

The report will be used over the next 100 days for the MAHA commission to fashion a plan that can be implemented during the remainder of President Trump’s term.

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under massive threat.

Dr. Ardem Patapoutian says he watches “with deep sadness as the United States’ remarkable scientific enterprise, which took generations of hard work and national investment to build, faces a concerted...

It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock indices toward a bear market, biotech M&A has been virtually nonexistent, wi...

A growing body of research suggests that preventing the viral infection can help stave off cognitive decline.

Why the ouster of Peter Marks, a senior FDA official, is a huge deal, whether you liked him or not.

Will Peter Marks' ouster from the FDA change how pharma industry engages with the Trump administration?

In his resignation letter, Dr. Peter Marks cited ‘misinformation and lies’ from Health and Human Services Secretary RFK Jr.

More than 1,600 readers answered our poll; many said they were looking for jobs in Europe and Canada.

What once belonged to all of us now belongs to corporations.

Regeneron’s investigational gene therapy has been tied to | Regeneron’s investigational gene therapy has been tied to notable hearing improvements in 10 of 11 children who were treated for a rare gene...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by a disease known as MASH.

The biggest medical advances of 2024 will be remembered as significant long into the future.